Abstract:
:The identification of molecular genetic biomarkers considerably increased our current understanding of glioma genesis, prognostic evaluation, and treatment planning. In glioblastoma, the most malignant intrinsic brain tumor entity in adults, the promoter methylation status of the gene encoding for the repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) indicates increased efficacy of current standard of care, which is concomitant and adjuvant chemoradiotherapy with the alkylating agent temozolomide. In the elderly, MGMT promoter methylation status has recently been introduced to be a predictive biomarker that can be used for stratification of treatment regimes. This review gives a short summery of epidemiological, clinical, diagnostic, and treatment aspects of patients who are currently diagnosed with glioblastoma. The most important molecular genetic markers and epigenetic alterations in glioblastoma are summarized. Special focus is given to the physiological function of DNA methylation-in particular, of the MGMT gene promoter, its clinical relevance, technical aspects of status assessment, its correlation with MGMT mRNA and protein expressions, and its place within the management cascade of glioblastoma patients.
journal_name
Onco Targets Therjournal_title
OncoTargets and therapyauthors
Thon N,Kreth S,Kreth FWdoi
10.2147/OTT.S50208subject
Has Abstractpub_date
2013-09-27 00:00:00pages
1363-72issn
1178-6930pii
ott-6-1363journal_volume
6pub_type
杂志文章,评审abstract:Background and aims:Gastric cancer (GC) is one of the most common cancers worldwide, and its pathogenesis is related to a complex network of gene interactions. The aims of our study were to find hub genes associated with the progression and prognosis of GC and illustrate the underlying mechanisms. Methods:Weighted gen...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S176511
更新日期:2018-10-02 00:00:00
abstract:Purpose:Intraoperative identification of rectal cancer (RC) can be challenging, especially because of fibrosis after treatment with preoperative chemo- and radiotherapy (CRT). Tumor-targeted fluorescence imaging can enhance the contrast between tumor and normal tissue during surgery. Promising targets for RC imaging ar...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S145473
更新日期:2018-03-23 00:00:00
abstract::Mesothelin (MSLN) is considered a promising target for cancer therapy. Originally extracted in 1992 after the immunization of mice with a human ovarian cancer (OC) cell line and cloned in 1996, MSLN seems to be involved in cell adhesion and metastasis. MSLN is prevalent in mesothelia tissues but is expressed in severa...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S145105
更新日期:2017-11-08 00:00:00
abstract:Objective:This study aimed to evaluate the safety and efficacy of intensity-modulated radiotherapy (IMRT) plus nimotuzumab with or without concurrent chemotherapy (CCT) for patients with locally advanced nasopharyngeal carcinoma (LA-NPC). Patients and methods:A total of 50 newly diagnosed patients with LA-NPC treated ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S151554
更新日期:2017-12-08 00:00:00
abstract:Purpose:It is widely known that some specific microRNAs can regulate the expressions of genes in gastric cancer cells at the post-transcriptional level. Previous studies have identified that miRNA-4766-5p was involved in tumor cell proliferation and can be an independent prognostic indicator for malignant pleural mesot...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S220234
更新日期:2019-10-16 00:00:00
abstract::Major advances in the understanding of the pathophysiology of melanoma have led to a new era of melanoma treatment with targeted therapy and immunotherapies. Since 2011, four new classes of medications with unique mechanisms of action have been approved, which allow melanoma to be treated at many different stages in i...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S171693
更新日期:2018-12-14 00:00:00
abstract:Objective:The objective of this study was to investigate the safety of robotic stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) patients and its related factors. Methods:A total of 74 HCC patients with Child-Turcotte-Pugh (CTP) Class A were included in a multi-institutional, single-arm Pha...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S142025
更新日期:2017-11-06 00:00:00
abstract:OBJECTIVE:Resveratrol is a phytoestrogen with various antiproliferative and proapoptotic effects. This in vitro study aimed to analyze the effect of resveratrol on the viability and expression of modulators of apoptosis in GH3 pituitary adenoma cells of the rat. METHODS:GH3 cells were incubated with resveratrol concen...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S45154
更新日期:2013-09-16 00:00:00
abstract::CD47 belongs to immunoglobulin superfamily and is widely expressed on the surface of cell membrane, while another transmembrane protein SIRPα is restricted to the surface of macrophages, dendritic cells, and nerve cells. As a cell surface receptor and ligand, respectively, CD47 and SIRPα interact to regulate cell migr...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S249822
更新日期:2020-09-22 00:00:00
abstract:AIMS:Metastasis-associated gene 2 (MTA2) is reported to play an important role in tumor progression, but little is known about the role of MTA2 in nasopharyngeal carcinoma (NPC). The aim of the study was to explore the expression and function of MTA2 in NPC. METHODS:Expression of MTA2 in NPC tissues and cell lines was...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S96518
更新日期:2016-03-18 00:00:00
abstract:Purpose:Paclitaxel resistance in ovarian cancer has become an urgent clinical problem. This study investigated the regulatory effects of RAB17 on the non-coding RNA network of the paclitaxel-resistant ovarian cancer cell A2780/PTX. Methods:Microarray analysis was used to identify differentially expressed genes in pacl...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S285153
更新日期:2020-12-24 00:00:00
abstract:Background:Bromodomain and extra-terminal domain inhibitors like JQ1 have proved to be promising epigenetic agents for the treatment of malignant ovarian carcinoma. However, the resistance of ovarian cancer cells to BET inhibitors has not been elucidated. In this study, we investigated the potential mechanisms underlyi...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S220267
更新日期:2019-10-03 00:00:00
abstract:Background:Celastrol is a major active component of the thunder god vine (Tripterygium wilfordii) used in traditional Chinese medicine to treat chronic inflammatory and autoimmune diseases. Celastrol inhibits PI3K-Akt-mTOR signaling, which is frequently dysregulated in tumors and critical for tumor-cell proliferation a...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S187315
更新日期:2018-12-11 00:00:00
abstract:BACKGROUND:Lapatinib is a dual epidermal growth factor receptor (EGFR) and HER2 inhibitor. Overexpression of these receptors is frequently observed in head and neck squamous cell carcinoma (HNSCC). As growing proportion of HNSCC is characterized by human papillomavirus (HPV) infection, we aimed at evaluating the effica...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S68235
更新日期:2015-02-02 00:00:00
abstract:Background:Several intracellular signaling pathways that are deregulated during hepatocarcinogenesis might constitute potential targets for hepatocellular carcinoma (HCC) therapy. The aim of this study was to test the potential synergic antitumor effect of salirasib and sorafenib in a diethylnitrosamine (DEN)-induced H...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S176903
更新日期:2018-10-17 00:00:00
abstract:BACKGROUND:Sunitinib is widely used as first-line treatment for metastatic clear cell renal cancer (MCRC). No reports are known of treatment after sunitinib failure. As irinotecan, cisplatin, and mitomycin-C (IPM) chemotherapy has been reported to influence MCRC after progression on cytokine therapy, we report on the o...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/ott.s3590
更新日期:2008-09-01 00:00:00
abstract:OBJECTIVE:To study microRNA (miR)-20a expression in hepatocellular carcinoma (HCC) and its effects on the proliferation, migration, and invasion of HepG2. METHODS:The real-time polymerase chain reaction was used to detect the expression of miR-20a in HCC tissue and normal tissue, as well as in HCC cell lines and norma...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S96861
更新日期:2016-05-27 00:00:00
abstract:Purpose:Aberrant activation of the Janus-associated kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is associated with increased malignant cell proliferation and survival. This Phase Ib study evaluated ruxolitinib, a potent JAK1/2 inhibitor, in combination with gemcitabine with or without n...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S157331
更新日期:2018-04-30 00:00:00
abstract:Purpose:B7 homologue 6 (B7-H6) has been found at an up-regulated level in multiple cancer cells and identified to be positively correlated with inferior clinical features. In non-Hodgkin lymphoma (NHL), however, the roles of B7-H6 and the underlying mechanism of action remain unclear. Through in vivo and in vitro exper...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S257512
更新日期:2020-06-18 00:00:00
abstract:Background and Objectives:Non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor (EGFR) mutation demonstrate only a median progression-free survival (PFS) of 8 to 10 months and undergo EGFR tyrosine kinase inhibitors (EGFR-TKIs) therapy. For decades, bilirubin has been reported to be assoc...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S266477
更新日期:2020-10-29 00:00:00
abstract:Background:The relationship of inflammation and tumor is becoming more and more important in the study on the pathogenesis of colorectal cancer. The role of TLR9-mediated immune inflammation reaction in the process is not currently clear. The purpose of the study was to discuss the correlation of TLR9 signal activation...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S174274
更新日期:2018-09-18 00:00:00
abstract::Lung cancer is the leading cause of cancer-related mortality in both sexes, accounting for over one quarter of cancer deaths. Non-small-cell lung cancer (NSCLC) comprises 85%-90% of lung cancer diagnoses and despite advances in multimodality therapies, 5-year survival rates remain dismal with a median survival for pat...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S67262
更新日期:2015-04-20 00:00:00
abstract:PURPOSE:This study aimed to explore the molecular mechanisms associated with bisphosphonate (BP)-related osteonecrosis of the jaw (ONJ) in patients with multiple myeloma (MM). METHODS:The gene expression profile GSE7116 was downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) fro...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S88463
更新日期:2015-09-22 00:00:00
abstract::Aberrant methylation of CpG dinucleotides is a commonly observed epigenetic modification in human cancer. Thus, detection of aberrant gene promoter methylation as a tool for diagnosis of tumors or as a prognostic marker has been widely described for many types of cancers, including nonsmall cell lung cancer (NSCLC). E...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S67355
更新日期:2014-10-31 00:00:00
abstract::Advanced gastric cancer (AGC) is difficult to treat with poor prognosis. Despite various possible treatments, the median survival time of such patients remains unsatisfactory. Therefore, new therapeutic approaches or combinations need to be further explored. We herein reported a case of a 54-year-old male patient who ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S221436
更新日期:2019-09-19 00:00:00
abstract:Introduction:Upper tract urothelial carcinoma (UTUC) is a relatively uncommon urologic malignancy for which there has not been significant improvement in survival over the past few decades, highlighting the need for optimal multi-modality management. Methods:A non-systematic review of the latest literature was perform...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S225301
更新日期:2020-01-06 00:00:00
abstract:Background:Cordycepin, the main active ingredient of a traditional Chinese herbal remedy - extracted from Cordyceps sinensis - has been demonstrated as a very effective anti-inflammatory and antitumor drug. The present study investigated its antitumor effect on pancreatic cancer, a highly aggressive cancer with extreme...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S164670
更新日期:2018-08-01 00:00:00
abstract:PURPOSE:Hypoxia is a common phenomenon encountered in solid cancers, leading to chemotherapy resistance and therefore to aggressiveness of the disease. The homeostatic response to hypoxia is mediated by hypoxiainducible factor-1 (HIF-1). The aim of this study was to investigate the impact of HIF1α in patients with prim...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S65373
更新日期:2014-09-11 00:00:00
abstract:Background/Aims:The effects of lncRNA-NORAD/mir-520a-3p on proliferation and invasion of non-small cell lung cancer (NSCLC) were studied, and its potential molecular mechanism was discussed. Methods:qRT-PCR was used to detect the expression of lncRNA NORAD and miR-520a-3p in non-small cell lung cancer tissues and cell...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S230954
更新日期:2020-02-19 00:00:00
abstract:Objective:As an epidermal growth factor, receptor-tyrosine kinase inhibitor (EGFR-TKI), gefitinib demonstrates a good therapeutic effect in patients with EGFR-mutant non-small-cell lung cancer (NSCLC). However, an overwhelming majority of these patients inevitably develop resistance against gefitinib. Unfortunately, th...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S220462
更新日期:2019-11-18 00:00:00